Tamura K - Search Results

1

Phase I and pharmacokinetic study of combination chemotherapy using irinotecan and paclitaxel in patients with lung cancer.

Asai G, Yamamoto N, Kurata T, Tamura K, Uejima H, Nakagawa K, Fukuoka M. Asai G, et al. Among authors: tamura k. J Thorac Oncol. 2006 Mar;1(3):226-30. doi: 10.1016/s1556-0864(15)31572-0. J Thorac Oncol. 2006. PMID: 17409861 Free article. Clinical Trial.

2

Ritterazine B, a new cytotoxic natural compound, induces apoptosis in cancer cells.

Komiya T, Fusetani N, Matsunaga S, Kubo A, Kaye FJ, Kelley MJ, Tamura K, Yoshida M, Fukuoka M, Nakagawa K. Komiya T, et al. Among authors: tamura k. Cancer Chemother Pharmacol. 2003 Mar;51(3):202-8. doi: 10.1007/s00280-002-0558-8. Epub 2003 Jan 14. Cancer Chemother Pharmacol. 2003. PMID: 12655437

3

Molecular target-based cancer therapy: tyrosine kinase inhibitors.

Tamura K, Fukuoka M. Tamura K, et al. Int J Clin Oncol. 2003 Aug;8(4):207-11. doi: 10.1007/s10147-003-0320-1. Int J Clin Oncol. 2003. PMID: 12955575 Review.

4

Effect of re-treatment with gefitinib ('Iressa', ZD1839) after acquisition of resistance.

Kurata T, Tamura K, Kaneda H, Nogami T, Uejima H, Asai Go Go, Nakagawa K, Fukuoka M. Kurata T, et al. Among authors: tamura k. Ann Oncol. 2004 Jan;15(1):173-4. doi: 10.1093/annonc/mdh006. Ann Oncol. 2004. PMID: 14679138 Free article. No abstract available.

5

Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small-cell lung cancer.

Kaneda H, Tamura K, Kurata T, Uejima H, Nakagawa K, Fukuoka M. Kaneda H, et al. Among authors: tamura k. Lung Cancer. 2004 Nov;46(2):247-54. doi: 10.1016/j.lungcan.2004.04.032. Lung Cancer. 2004. PMID: 15474673

6

Gefitinib in non-small cell lung cancer.

Tamura K, Fukuoka M. Tamura K, et al. Expert Opin Pharmacother. 2005 Jun;6(6):985-93. doi: 10.1517/14656566.6.6.985. Expert Opin Pharmacother. 2005. PMID: 15952926 Review.

7

Small interfering RNA targeting survivin sensitizes lung cancer cell with mutant p53 to adriamycin.

Yonesaka K, Tamura K, Kurata T, Satoh T, Ikeda M, Fukuoka M, Nakagawa K. Yonesaka K, et al. Among authors: tamura k. Int J Cancer. 2006 Feb 15;118(4):812-20. doi: 10.1002/ijc.21350. Int J Cancer. 2006. PMID: 16108013

8

Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib.

Ando M, Okamoto I, Yamamoto N, Takeda K, Tamura K, Seto T, Ariyoshi Y, Fukuoka M. Ando M, et al. Among authors: tamura k. J Clin Oncol. 2006 Jun 1;24(16):2549-56. doi: 10.1200/JCO.2005.04.9866. J Clin Oncol. 2006. PMID: 16735708

9

A phase I study of irinotecan in combination with amrubicin for advanced lung cancer patients.

Kaneda H, Kurata T, Tamura K, Uejima H, Nakagawa K, Fukuoka M. Kaneda H, et al. Among authors: tamura k. Anticancer Res. 2006 May-Jun;26(3B):2479-85. Anticancer Res. 2006. PMID: 16821636 Free article. Clinical Trial.

10

Down-regulation of survivin by ultraviolet C radiation is dependent on p53 and results in G(2)-M arrest in A549 cells.

Ikeda M, Okamoto I, Tamura K, Satoh T, Yonesaka K, Fukuoka M, Nakagawa K. Ikeda M, et al. Among authors: tamura k. Cancer Lett. 2007 Apr 18;248(2):292-8. doi: 10.1016/j.canlet.2006.08.005. Epub 2006 Sep 7. Cancer Lett. 2007. PMID: 16959403

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,368 results

Search Page

Filters